Filter posts

Greenwood: A Critical Medicare Policy Has Been Delayed. Let’s Use This Opportunity to Get It Right...

In a piece for Morning Consult, BIO’s Jim Greenwood writes that while CAR-T cell therapies …

Greenwood : In Drug Pricing Debate, Politicians and Patients Are Not Talking About Same Price

Summary: BIO CEO Jim Greenwood gave the following keynote address at the BIO 2019 International …

New BIO Report on State of Innovation for Alzheimer’s Disease Therapeutics

Today, BIO released a new report: The State of Innovation in Highly Prevalent Chronic Diseases …

“Health Care’s Big Spending Mismatch”

This week, Axios reported on new data that shows “the health care services that rack …

Greenwood: In Pharma Value Chain, PBMs Manage to Benefit

Writing for The Hill, BIO’s President and CEO Jim Greenwood offered praise to the Senate Finance …

Kentucky Officials Expose PBMs for Gaming the System

While many were watching the drug pricing debate unfold on Capitol Hill, the Kentucky Cabinet …

Two New Infographics Illustrate the Success of the Orphan Drug Act

In recognition of Rare Disease Day, BIO’s Jim Greenwood shared commentary on LinkedIn celebrating the …

Health Care in Focus as President Trump Addresses the Nation

In his State of the Union address, President Trump described the need to rein in …

Greenwood Shines Spotlight on Insurance Industry Rip-off

Writing for The Hill, BIO’s President and CEO Jim Greenwood shined a spotlight on a …

The Right Way to Address Prescription Drug Costs

Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City …